Compare · ARGX vs CLDI
ARGX vs CLDI
Side-by-side comparison of argenx SE (ARGX) and Calidi Biotherapeutics Inc. (CLDI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CLDI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 16204.9x CLDI ($3.4M).
- Over the past year, ARGX is up 51.2% and CLDI is down 95.6% - ARGX leads by 146.8 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 2 for CLDI).
- Company
- argenx SE
- Calidi Biotherapeutics Inc.
- Price
- $882.63-1.03%
- $0.17+5.22%
- Market cap
- $54.76B
- $3.4M
- 1M return
- +12.11%
- -18.20%
- 1Y return
- +51.24%
- -95.57%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- 2021
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 2
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest CLDI
- Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
- SEC Form DEFA14A filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
- Calidi Biotherapeutics Provides Required NYSE American Disclosure
- SEC Form SCHEDULE 13G filed by Calidi Biotherapeutics Inc.
- SEC Form 10-Q filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
- Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston